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CBackground: Substantial immunological improvement has been re-
ported for HIV-infected patients who switch from a failing regimen to a
protease inhibitor regimenwith Lopinavir/ritonavir (LPV/r). We use de-
cision analysis modeling to estimate health and economic conse-
quences expected from this switch. Methods: A Markov model com-
bined best evidence for CD4 T-cell response, infectious disease
events, death rates, and quality of life for African populations with
Kenyan andUgandandata ondrug andmedical care costs.We estimate
the incremental cost-effectiveness ratio of switching to an LPV/r-based
regimen versus remaining on a failed first antiretroviral (ARV) regimen
or discontinuing all ARV drugs. The model assumes concurrent use of
cotrimoxazole, and 4% annual loss to follow-up. Local effects due to
prevalence of malaria and tuberculosis are included in themodel. Sen-
sitivity analysis examines the effects of varying disease, ARV therapy
and CD4 T-cell cost, and ART discontinuation assumptions.
esults: The base model estimates an improvement of 20 months in O
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doi:10.1016/j.jval.2011.06.011verage survival for the LPV/r group. The respective LPV/r ICER for
enya is $1483 per quality-adjusted life year (QALY) compared to
1673/QALY for Uganda. The ICERs increase to $1517 and $1707, respec-
ively, if CD4 T-cell tests cost $25. The model comparing switching to
PV/r to discontinuing all ARV drugs decreases both costs and benefits
roportionally for the treatment groups. Conclusion: The estimates
re clearly below themost stringentWorld Health Organization bench-
ark for cost-effectiveness for Kenya and within the acceptable range
f cost-effectiveness for Uganda. Thus, the switch to second-line ther-
py with LPV/r in these countries appears to be a cost-effective use of
esources.
eywords: Africa, AIDS, cost-utility analysis, decision analysis model,
odeling.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
A large amount of resources, both economic and human, have
been focused on the HIV/AIDS pandemic in sub-Saharan Africa,
and especially on enabling universal access to antiretroviral (ARV)
therapy (ART) for people living with HIV/AIDS [1,2]. Much of the
focus has rightfully been on scaling up to provide first-line ART [3].
However, as the scale up is implemented, increasingly complex
issues, beyond those of simply rolling out the least expensive ARV
regimen to as many individuals as possible, must be considered.
One issue is related to focusing on providing a primary low-cost
ARV regimen to as many individuals as possible versus providing
a second, often more costly, regimen to those in whom their first
ARV regimen failed.
In high-income countries, discussions of resource decisions
are increasingly informed by economic studies. However, in re-
source-limited countries, the insights of economic analyses have
not been frequently used to inform discussions of the use of ex-
pensive drugs that have emerged over the past 20 years [4]. A
number of recent studies [2,5–9] have provided valuable informa-
ion on some of the cost or cost-effectiveness issues related to
nterventions associated with the HIV/AIDS epidemic in Africa,
* Address correspondence to: Kit N. Simpson, Department of Heal
151B Rutledge Ave., Charleston, SC, 29425 USA.
E-mail address: simpsonk@musc.edu.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.ut additionalworkwill be needed as our understanding of clinical
nd epidemiological complexities in the HIV/AIDS epidemic in
ow-income countries increases [10–12]. Recent clinical and epide-
iological study findings indicate that the consideration of im-
rovements affected by ART in patients with HIV/AIDS in African
opulations are inadequate without also considering issues re-
ated to tuberculosis (TB) andmalaria [13–15]. Budgets andmacro-
conomic factors vary greatly across countries in Africa [16–21].
hus, a cost-effectiveness ratio for one country or setting may be
isleading if used to inform discussions in other settings [22].
This study provides an example of how we may approach the
ask of providing needed economic information for informing dis-
ussions related to the use of scarce resources for managing HIV/
IDS in Africa. It integrates data from an unpublished presenta-
ion [23] reporting important outcomes for 477 patients in the
DART (Development of AntiRetroviral Therapy in Africa) study
who switched to second-line ARV treatment with cost data from
Uganda and Kenya. It uses transition matrices that capture disease
progression reported for the DART study [23] at 1 year and uses a
second matrix in subsequent years to reflect the expected progres-
sion for a population managed by CD4 T-cell monitoring [24]. The
bjectives of the studywere to use theDART studyCD4T-cell count
adership and Management, Medical University of South Carolina,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1049V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 4 8 – 1 0 5 4increases reported for the 477 patientswho switched from the initial
non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen to a
boosted protease inhibitor (PI) regimen to:
1. Compare the estimated survival benefits and costs for popula-
tions in Uganda and Kenya who are switched to a PI-based reg-
imen of lopinavir  ritonavir (LPV/r)  zidovudine (ZDV) and
lamivudine (3TC) to remaining on a failing first-line regimen
. Examine the effects of prophylaxis with cotrimoxazole for in-
fectious events, effect of cost of CD4 T-cell testing, and effects
of variations in rates of malaria on model estimates of incre-
mental cost-effectiveness, survival, and expected expenditure
for persons treated in Uganda and Kenya
Methods
Recent reports from the DART trial indicate a median increase of
204 CD4 T cells at 48 weeks after switching from the failing first-
line ART (nevirapine) to a PI-based regimen with LPV/r [23]. The
effectiveness of switching is dependent on the application of strin-
gently defined and operational switching criteria. DART switch
criteria are any one of the following: 1) new or recurrent World
Health Organization (WHO) stage 4 event, 2) multiple new or re-
current WHO stage 3 events, 3) CD4 T-cell count less than 100
cells/mm3 after 48 weeks.
The objective of this study was to estimate the long-term
ealth and economic consequences expected as a result of the
D4 T-cell increase observed after the switch from a failing first-
ine regimen to a PI-based regimen for patients in Uganda and
enya. AMarkovmodel was used to capture cost and benefits over
he lifetime of a patient cohort and also to project 5-year cost
stimates.
Population
The model’s population assumptions are based on the character-
istics of the patients enrolled in the DART trial [25]. The most
important of these assumptions are related to the baseline im-
mune status asmeasured by the distribution of CD4T-cell counts
and a history of twoWHO stage 3 events or a current WHO stage 4
event.
The DART trial [26] is a multicenter, open-label study that ran-
domized 3316 ARV-naïve patients in Uganda and Zimbabwe to
clinical monitoring only or clinical plus laboratory monitoring
while on a regimen of ZDV/3TC  tenofovir, abacavir, or nevira-
pine (NVP). The 477 patients in whom this first-line regimen failed
by the criteria mentioned previously were switched to a second-
line regimen composed of LPV/r  NNRTI  nucleoside reverse
transcriptase inhibitor (NRTI) or LPV/rNRTIs [23,26]. Themedian
and interquartile range (IQR) of CD4 T-cells/mm3 at baseline (at
ailure of first-line and switch to second-line) were 46 CD4 T-
ells/mm3 and an IQR of 23 to 84 CD4 T-cells/mm3, respectively;
this increased to 250 CD4T-cells/mm3 at 48weeks,with an IQR of
165 to 340 CD4 T-cells/mm3 for patients whowere switched to an
LPV/r regimen [23]. Because the DART switching trial had no com-
parison arm, the base-casemodel assumes that patientswhowere
not switched would remain on their initial ART and would have
the same baseline CD4 T-cell count, which would decrease by 20
D4 T-cells/mm3 per quarter based on estimates for patients in
whom treatment failed or untreated patients reported in the liter-
ature [5,27]. An alternative scenario explores the result of no ART
after the initial ARV regimen fails in patients. The difference illus-
trated under this assumption captures the avoided costs after a
discontinuation of the failed regimen and the more rapid CD4T-cell decrease expected for patients who are not on any ART.Model description
The Markov model used to capture the treatment-modified dis-
ease progression of HIV/AIDS patients on the new ARV regimens
has five transitional health states defined by CD4 T-cell ranges
and two absorbing health states that capture death related to HIV
disease anddeath related tomalaria or other causes. The structure
of the model is depicted in Figure 1. This structure is a simplifica-
tion of a previously developed model used in resource-rich coun-
tries that included viral load levels in the model health state def-
inition [28]. The health states are defined as 1)more than 500 CD4
T cells; 2) 350 to 500 CD4 T cells; 3) 200 to 349 CD4 T cells; 4) 50 to
199 CD4 T cells; 5) fewer than 50 CD4 T cells; 6) death from AIDS
or infection; 7) death from malaria. Transitions between the
health states in the model are assumed to cycle every 3 months.
The model counts the number of individuals in each of the health
states once in each 3-month cycle; estimates the number of dis-
ease events for the population occupying each live health state for
that model cycle; assigns a cost per event, the cost of a visit, and
the cost of ARV drugs for each health state; and totals these costs
and months of survival for that cycle. The rate of progression be-
tween the health states in the model is determined by two transi-
tion matrices. The first transition matrix is calculated from the
results at 48 weeks from the DART trial. This rate of response
reflects patients who are switched to a regimen containing at least
two active drugs. A second transition matrix is used after the first
year in themodel. This transitionmatrix is based on archival data
from patients on ART who were monitored only by CD4 T-cell
count changes after the first year of treatment. These data were
collected during 1994 to 1996 for AIDS patients on PI-based regi-
mens that were monitored only with CD4 T-cell counts. These
transitions capture the assumption that the major improvement
in patients’ immune status takes place during the first 48 weeks
after the initiation of a new ARV regimen and that the type of
monitoring test used could affect patients’ rates of progression.
The transition matrix for the comparison group who are not
switched to a PI regimen are derived from the literature [5,29]. The
transition matrices used in the model are provided in the Appen-
dix found at doi:10.1016/j.val.2011.06.011. Themodel assumes that
the first ARV regimen consists of an NNRTI  two NRTI drugs
because themajority of first regimens in Uganda and Kenya today
contain an NNRTI and two NRTI drugs. This assumption allows us
to use themost appropriate costs to inform current decisions. The
base model assumes that the PI regimen consists of LPV/r  two
NRTI drugs. Themodel reflects the ARV regimen failure rate in the
DART trial, and failure is thus defined as a newWHO stage 4 event
Fig. 1 – Model structure.or two ormore newWHO stage 3 events [30] or a decrease to or less
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regimen. The structure of the model is depicted in Figure 1.
Events
The distribution of the total population among the five health
states in the model captures the immune status of the population
and thus determines the rate at which patients experience AIDS
and other infectious disease events and die as a result of these
conditions. The types of events associated with immune status
include isosporiasis, toxoplasmicmeningitis,Mycobacterium avium
complex, TB, other severe infections, and other mild infections
[5,31]. The infectious event rates used in themodel are specific for
eachmodel CD4 T-cell stage, as those reported by Goldie et al. [5]
nd described in Table 1. Because the clinical event rates are spec-
fied as quarterly risks of an event happening for each CD4 T-cell
count category, they are applied to the number of individual who
occupy the CD4 T-cell category during eachmodel cycle iteration
and summed at the end of the model. Thus, if health state 1 is
occupied by 50 patients during time 1 and by 80 patients during
time 2 and the event risk is 2%, then the number of events at the
end of time 2will be (50 0.02) (80 0.02) 2.6 expected events.
This approach avoids having to use specific health states for each
type of event and allows us to still include valid infection event
estimates for each time period.
Malaria events and death frommalaria or other causes that are
not associated with AIDS, however, can also occur in the model.
The rates of malaria and the cost of malaria episodes were based
on data reported by Reyburn et al. [32]. These rates are applied to
all persons still alive in themodel for each time period. This allows
themodel to capture both the costs and competing causes of death
due to TB andmalaria. This is important for amodel that is used to
predict events and costs in environments where the average life
expectancy is low and competingmortalitymayhave a large effect
on both the benefits and costs related to a disease-specific inter-
vention. The benefit of treatment is estimated in years of survival.
The incremental cost-effectiveness ratios (ICERs) are calculated
based on taking the discounted difference in the total health-care
cost for the LPV/r and NNRTI cohorts and dividing this difference
by the differences in discounted quality-adjusted life years
(QALYs) for the two cohorts expressed for the model year 2007.
The discount rate used is the standard prescribed for US economic
analyses. This was used because no specific rates for Kenya or
Uganda were published in the literature. This rate converts the
value of future costs and benefits to the model base year, which is
Table 1 – Quarterly risk of clinical event by health state wi
to model cotrimoxazole prophylaxis.
Event type
1 2
Mild infections 0.01358 0.01358
Severe infections 0.00680 0.00680
Isosporiasis 0.00010 0.00010
Toxoplasmic encephalitis 0.00000 0.00000
Mycobacterium avium 0.00000 0.00000
Tuberculosis 0.00614 0.00614
Mild other 0.01521 0.01521
Severe other 0.01521 0.01521
Malaria 0.00020 0.00020
Death: severe infection* 0.2499 0.2499
Death: other cause* 0.0049 0.0049
Death: malaria† 0.120 0.120
* Sources: Mermin et al., 2004 [39]; Goldie et al., 2006 [5].
† Source: Reyburn et al., 2004 [32].2007, and is not related to the potential inflation rates in a country.Quality-adjusted survival
At present, only summary utility weights assigned toWHO health
states by a subgroup of individuals enrolled in theDART cohort are
available [33]. The specific health states used to solicit these values
are based on theWHO classification for HIV/AIDS. In contrast, the
model health states are defined by CD4 T-cell count ranges. One
may expect, however, relatively high congruence between the
WHO stages and our CD4 T-cell count–defined model health
tates. Thus, we used the mean utility values reported by Medina
t al. [33], which appear to adjust for differences in quality of life
or the health states. The values used are listed in Table 2. Pub-
ished values for QALYweights by CD4T-cell groups are available
or patients in high-income countries. However, wewere reluctant
o use these values for several reasons. The values from the Afri-
an cohort are from theDART trial andmay therefore better reflect
he health-related quality of life experienced for patients living in
n environment with little technology available to assist with
aily activities andwith greater difficulties in gettingmedical care.
ndeed, as would be expected, the values reported byMedina et al.
33] for African populations are lower across all health states than
alues published for patients in high-income countries [34–36].
he African values also exhibit a substantially higher differential
etween high and low health state parameters than the published
alues that are derived from populations in high-income coun-
ries. QALYs are discounted at 3% per year for the base model
hen they are used to estimate an ICER.
t cotrimoxazole prophylaxis and the relative risk applied
th state RR with
cotrimoxazole
3 4 5
02237 0.03568 0.05991 0.484
01512 0.02192 0.02344 0.498
00020 0.00050 0.00159 0.818
00008 0.00034 0.00042 0.832
00000 0.00123 0.03108 0.591
00982 0.01104 0.01350 0.591
01926 0.02423 0.04319 0.591
04025 0.07816 0.086750 0.591
00020 0.00020 0.00020 0.884
2499 0.2499 0.2499 0.51
0049 0.01338 0.13226 0.51
120 0.120 0.120 0.51
Table 2 – Utility weights used in the model.
Model health
state
CD4 T-cell
range
WHO stage match Utility
weight
1 500 cells/ml Symptomatic HIV .75
2 350–500 cells/ml Symptomatic HIV .75
3 200–349 cells/ml Minor AIDS-defining
illness
.49
4 50–199 cells/ml Mean of minor and
major AIDS-
defining illness
.35
5 50 cells/ml Major AIDS-defining
illness
.20thou
Heal
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.WHO, World Health Organization.
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The annual cost of the second-line therapy LPV/r component in
the model is assumed to be $500. The cost of the NNRTI compo-
nents is assumed to be a weighted average of NVP and efavirenz,
which cost $71 per year. The costs used in the model are provided
as quarterly costs (Table 3, 2007 US currency) for the ARV regi-
mens, cost of cotrimoxazole used for prophylaxis against Pneumo-
ystis pneumonia and other AIDS-related illnesses, the cost of
D4 T-cell monitoring and monitoring visits every 6 months, as
ell as the cost of treatments for episodes of infectious events and
alaria. The cost perspective used in the model is that of the
ealth system for 2007. Because no indirect cost weights are as-
igned, the model will tend to underestimate the cost-effective-
ess that would be expected if a societal costing perspective were
sed. The cost weights and the data sources for the weights used
n the model are provided in Table 1. Costs are discounted at 3%
er year for the base model when it is used to estimate an ICER.
Results
The base model estimates an improvement of 20 months in aver-
age survival for the LPV/r group at an ICER of $1673/QALY for
Uganda and $1483/QALY for Kenya (Table 4). The ICER increases to
$1687 (Uganda) and $1487 (Kenya) if CD4 T-cell tests cost $25
nstead of $3 and improves to $1328/QALY (Uganda) and $1329/
ALY (Kenya) when we assume no use of cotrimoxazole (Table 5).
he survival benefit due to the LPV/r regimen, however, decreases
rom 20months for the basemodel to 13monthswhen cotrimoxa-
ole prophylaxis is excluded from the model. When we compare
witching patients to the LPV/r regimen to the discontinuation of
ll ARV drugs for the comparison group (assuming no use of cot-
imoxazole in either group), the ICER is $1570 (Kenya). In this same
cenario, when the use of cotrimoxazole is retained in the LPV/r
egimen group only, survival improves by 55.7 months (4.6 years)
nd the ICER is $1266/QALY (Kenya). Doubling the malaria inci-
ence has no effect on the ICER when we assume that cotrimoxa-
ole is used, but increases the ICER from $1329/QALY to $1346/
ALY (Kenya) when we assume no use of cotrimoxazole.
The DART trial results were based on data from 477 patients.
hemodel included all those data, but for ease of interpretation to
ohorts of different sizes, we report themodel costs and outcomes
or a cohort of 100 people over the first 5 years after the time of ART
Table 3 – Cost parameters used in the base model and sen
Variable Cost per event:
Uganda, $
Mild infectious event 30
Severe infectious event 90
Isosporiasis event 60
Mycobacterium avium event 60
Toxoplasmic encephalitis 60
Tuberculosis event 60
Mild other event 30
Severe other event 60
Malaria 41
Routine visit 5
CD4 T-cell count† 3
LPV/r, AZT, 3TC per quarter † 155.50
NVP, ATZ, 3TC per quarter† 44
Cotrimoxazole per quarter† 54.75
AZT, azidothymidine; LPV/r, lopinavir/ritonavir; NVP, nevirapine; 3T
* Source: Diagbouga et al., 2003 [40].
† Source: .Médecins Sans Frontières. Untangling the web of price redwitch. We used these estimates to calculate the average yearlyost per additional patient switched to an LPV/r regimen com-
ared to the cost of remaining on an NNRTI regimen (Table 4).
hese costs are not simply the added drug costs per patient be-
ause patients on the two regimens die at different rates. Thus,
sing the mean incremental added cost per year for ART, cotri-
oxazole and CD4 T-cell testing are the most appropriate mea-
sures for predicting the true budget impact of switching ARV reg-
imens. The budget estimates at 5 years for a representative cohort
of 100 patients started on an LPV/r regimen are always higher than
the estimates for a cohort that remains on a failing NNRTI regi-
men. This is both because of the higher ARV costs and because
fewer patients die; thus, more patients will still need care over the
5 years on the ARV regimen that has not failed. For each patient
switched to the LPV/r regimen, a clinic should expect to increase
the CD4T-cell testing budget by $0.70 per year, the cotrimoxazole
budget by $25.42 per year, and the ARV budget by $361 per year.
ity analyses (2007 US$)*.
Cost per event:
Kenya, $
Range tested for
sensitivity analysis, $
30 24–36
90 78–108
61 48–72
61 48–72
61 48–72
61 48–72
30 24–36
61 48–72
41 33–49
5 4–6
3 12 and 25
158 124.40–186.60
50 35.20–52.80
2.43 43.80–65.70
ivudine.
ns, July 2007 [41].
Table 4 – Results of base model estimates for Uganda
and Kenya.
LPV/r
regimen
NNRTI
regimen
Difference
Uganda
Mean life expectancy per
patient in years
6.1 4.4 1.7
Total QALYs per 100
patients*
314 142 172
Total lifetime cost per
100 patients, $*
473,542 185,656 287,886
ICER, $ 1673
Kenya
Mean life expectancy per
patient in years
6.1 4.4 1.7
Total QALYs per 100
patients*
314 142 172
Total lifetime cost per
100 patients, $*
366,422 111,202 255,219
ICER, $ 1483
ICER, incremental cost-effectiveness ratio; LPV/r, lopinavir/ritona-
vir; NNRTI, non-nucleoside reverse transcriptase inhibitor; QALYs,
quality-adjusted life-years.sitiv
C, lam* Discounted by 3% per year.
not r
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model estimates for 100 patients and can be used for planning
purposed for programs in which their budget projections reflect
the fact that more individuals will be alive and in care each year
for a patient cohort who is switched to the PI-based regimen
than those in a cohort who remain on the failing regimen and
that not all the patients who switched will remain on the PI-
based regimen for a full 5 years. The base results for Uganda and
Kenya are presented in Table 4. Thus, although not classic bud-
get-impact figures that capture all expected changes in drug
uptake and populations covered, these marginal cost-impact
measures may be used to assist programs in constructing local
budget-impact models that reflect changes in both drug uptake
and population size.
Table 5 – Results of sensitivity analyses for Uganda*.
Model assumptions Added months of
survival
Inc
co
Baseline estimates 20.0
Change ARV regimens to reflect drug
use in DART trial
20.0
Increase all costs by 20% (excluding
ARV and cotrimoxazole)
20.0
Decrease all costs by 20% (excluding
ARV and cotrimoxazole)
20.0
No discounting of cost and benefits 20.0
Increase CD4 T-cell test cost to $25 20.0
Discontinue ART at time of switch
for comparison group (retain
cotrimoxazole in LPV/r group)
55.8 (4.6years)
No cotrimoxazole 13.3
No cotrimoxazole for either arm and
no ART for comparison group
13.3
Rate of malaria from Kasirye et al.,
2009 [15], no cotrimoxazole for
either arm and no ART for
comparison group
13.3
ART, antiretroviral therapy; ARV, antiretroviral; ICER, incremental co
* The results for Kenya were of similar magnitude and are therefore
Fig. 2 – Cost-effectiveness acceptability curve for Uganda sh
compared to not switching for different ICERs.Sensitivity Analysis
Themodel’s estimated ICERs for Kenya andUgandawere robust to
changes in most of the variables used in the analysis, and the two
country models behaved similarly in the sensitivity analysis. For
that reason, only the results for Uganda are reported in the sce-
nario sensitivity analysis (Table 5) and in the probabilistic sensi-
tivity analysis (Fig. 2). When we tested the model’s sensitivity to
change for Uganda, assuming that there was no use of cotrimoxa-
zole for either group, the ICER was $1579/QALY, and when all ART
also was discontinued at the time of switching for the NNRTI reg-
imen comparison group, the ICER was $1538/QALY (Table 5). The
model estimate changed minimally from an ICER of $1649/QALY
for the base model to $1729/QALY when the actual ART mix from
the DART switch trial was used. For Uganda, the effect of doubling
e in ARV
r patient
ear, $
Increase in
cotrimoxazole cost
per patient per
year, $
ICER, $ Percentage of
change in
ICER from
baseline
1649
63 25 1729 5
51 28 1641 0.5
51 28 1657 0.5
51 28 1631 1
51 28 1687 2
57 161 1652 0
95 0 1328 19
29 0 1538 7
25 0 1528 7
ectiveness ratio; LPV/r, lopinavir/ritonavir.
eported.
g the probability that switching to LPV/r is cost-effectivereas
st pe
per y
3
3
3
3
3
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1053V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 4 8 – 1 0 5 4the malaria incidence has no effect on the ICER when we assume
that cotrimoxazole is used and improves the ICER from $1649/
QALY to $1159/QALY when we assume no use of cotrimoxazole.
The combined effects of all changes in themodel parameters
and the assumption of a 10% variation in the model transition
rates were tested in a probabilistic sensitivity analysis using
Crystal Ball software to perform 30,000 probabilistic estimates
using the model for Uganda. Costs of events were assumed to
have a log-normal distribution, whereas cost of medications,
medical visits, and tests were assumed to have a triangular
distribution. Risks of events and transitions to new health
states had a beta distribution, and utility weights were normally
distributed. Correlations between model parameters were not
defined. Thus, the estimates may have a larger spread than
would be expected if correlations were known. The results of
the probabilistic sensitivity analysis were used to estimate a
cost-effectiveness acceptability curve in Figure 2.
The budget estimates were quite sensitive to some of the
changes made. The expected ART cost increase per patient who
was switched to the LPV/r regimen was $361 per year in the base
estimate. This number changes to $229 per patient per year when
we assumed that no cotrimoxazole was given and decreased fur-
ther to $193 if malaria rates were assumed to be 12% per year and
no cotrimoxazole was provided. It is important, however, to real-
ize that these savings are due strictly to the increased deaths that
remove patients from the care system. These ARV budget-impact
figures demonstrate clearly why it is unwise to rely exclusively on
cost estimates or a budget-impact model to inform treatment pol-
icy. The results of the sensitivity analysis for Uganda are depicted
in Table 5.
Discussion
We used decision analysis modeling to estimate health and eco-
nomic consequences expected for HIV-infected patients who
switch from a failing ARV first-line regimen to a PI regimen with
LPV/r based on data reported in the DART trial poster presented by
Chimbetete et al. [23]. Themodel was structured as aMarkov tran-
sition model in Microsoft Excel and combined the best evidence
for CD4 T-cell response, infectious disease events, death rates,
nd health-related quality of life for African populationswith Ken-
an and Ugandan data on drug and medical care costs. We esti-
ated the ICER of switching to an LPV/r-based regimen versus
emaining on a failed first ARV regimen or to discontinuing all ARV
rugs. The model assumed concurrent use of cotrimoxazole, and
% annual loss to follow-up. Local effects due to prevalence of
alaria and TB were included in the model. Sensitivity analysis
xamined the effects of varying disease, ARV, and CD4T cell cost,
nd ARV discontinuation assumptions. The base model estimates
n improvement of 20 months in average survival for the LPV/r
roup. The respective LPV/r ICER for Kenya is $1483/QALY com-
ared to $1673/QALY for Uganda.
These estimates have several limitations. First, the data on the
ffect of switching patients from a failed first ARV regimen are
rom an unpublished study describing the CD4 T-cell count in-
reases observed in 477 patients in the DART trial. Although the
oster that we used to model the CD4 T-cell increases were well
described in the poster graphs, these data have not undergone
peer review and may not reflect the final findings from the study.
This must be considered in the interpretation of our results. Sec-
ond, patients in the DART trial were monitored by nurses every 4
weeks and were highly adherent to both their visit schedule and
taking their ARV drugs [26]. Patients in other settings may exhibit
poorer patterns of adherence and/or they may be monitored less
often, which may decrease switching effectiveness and lower
cost-effectiveness. Additionally, the costs used for visits in this
model and the practice patterns underlying these costs will varyby location and by health-care system infrastructure. Thus, cost-
effectiveness may be negatively affected in locations with less ef-
ficient health-care systems.
The model was also limited in its ability to capture any de-
crease in patient adherence to an ARV regimen that may be ex-
pected to take place after the end of the DART trial data. Although
the model captures complete discontinuation, its structure does
not allow us to capture decreasing adherence, except as it is in-
cluded in the progression between health states that is guided by
the model transition matrices.
A Markov model is a structure that allows us to integrate data
from different sources under clearly specified assumptions. Such
models may contain two types of errors that could affect the
model estimates. The first is an error in the structure of themodel
itself; the second ismis-estimation of the parameters used to pop-
ulate the model. We feel quite confident that the present model
with its five health states based on CD4 T-cell distribution is an
appropriate structure for thismodel. CD4T-cell counts have been
sed to differentiate the risk of AIDS events and death in HIV-
nfected populations for many years and are clearly used in prac-
ice to make ART switching decisions. They were collected care-
ully and under clinical trial quality control conditions in theDART
rial; thus, they may be expected to do well at capturing the im-
une status of trial participants in the model, giving us high con-
dence in the validity of the model’s structure.
We clearly cannot have a similar level of confidence in the
arameters that we used to populate the model because they
ome from many sources and time periods. Thus, we examined
he individual and joints effects of changing themodel parameters
n the sensitivity analyses. As may be seen in Table 5, few of the
ariations in the model parameters have a large individual effect
n the estimated ICERs. The mean budget impact figures, how-
ver,may change substantiallywith changes inmodel input costs.
he effect of the cost of CD4 T-cell monitoring is important to
ote. Themodel assumed that each test cost $3.00. If this assump-
ion is changed to use a cost of $25.00 per test, then the ICER
hanges by about 3%. This is an important finding because the
bjective of the DART trial was to compare outcomes for patients
anaged with and without the use of this test. Thus, it is impor-
ant to note that testing costs had a small butmeasurable effect on
he cost-effectiveness of ART switching.
It is important to note the very large changes in the per-person
udget impact thatwe showunder the different assumptions used
n the sensitivity analysis. It is common practice to estimate the
udget impact based onmeanper-person costwith the rate of new
eople added to each year’s cohort. In the case of second-line ART,
e would multiply the number of individuals switched each year
y $361 (mean cost per person per year) and calculate a total for a
pecific time period. The estimated budget impact, however,
ould be 37% too high if patients received cotrimoxazole because
ur model shows that the annual per-person cost decreases from
361 to $229 when no cotrimoxazole use is assumed. The esti-
ated budget impact would be even less for groups in areas with
igh rates ofmalaria, where themarginal annual cost is estimated
o be $119. This is a very important finding from the modeling
tudy, which indicates that budget impact estimates should take
ocal epidemiology and practice patterns into account before de-
isions are made about affordability.
Conclusion
The estimates of the model indicate that under the WHO bench-
mark threshold for cost-effective ICERs [37], a strategy of switch-
ing to LPV/r appears to be acceptably cost-effective for this region.
The WHO benchmark defines an acceptability threshold based on
one to three times a country’s per-capita gross domestic product
(GDP). Uganda’s 2007 GDP was $1100 [38] and Kenya’s 2007 GDP
([
[
[
[
[
[
[
1054 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 4 8 – 1 0 5 4was $1700. Thus, an ICER of $1673/QALY (Uganda) is 1.5 times the
UgandanGDP and $1483/QALY (Kenya) is 87% of the GDP for Kenya
for a switch to an LPV/r-based regimen using stringent clinical or
immunological failure criteria, which appears to be quite cost-
effective for Kenya and probably acceptable for Uganda.
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